This announcement is a separate document:
あすか製薬ホールディングス：難吸収性リファマイシン系抗菌薬「リフキシマ錠（リファキシミン）」の小児に対する用法及び用量の追加に係る製造販売承認事項一部変更承認取得のお知らせ
ASKA Pharmaceutical Holdings: Notice of obtaining approval for partial changes in manufacturing and sales approval matters relating to the addition of usage and dosage for children of the hardabsorbable rifamycin antibacterial drug “rifuxima tablets (rifax
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.